Lead to the right advice globally

Anti-dumping, Countervailing & Trade Remedies

Support investigations and proceedings for anti-dumping, countervailing, safeguards, and other trade remedies, including evidence preparation and hearing strategy.

Antitrust / Merger Control Filings

Prepare and submit merger control notifications, manage authority engagement, and coordinate remedies to secure antitrust clearance on time.

Audit Services

Provide statutory and special-purpose audits, assisting with financial statement assurance, internal control review, and reporting requirements for stakeholders and regulators.

Backdoor Listing / Reverse Takeover

Advise on backdoor listings and reverse takeovers, including target selection, transaction structuring, regulatory pathways, and disclosure compliance.

China ODI Approval / Filing

Support China outbound investment (ODI) approval/filing with NDRC/MOFCOM and related foreign exchange procedures, ensuring end-to-end regulatory compliance.

Customs Compliance Services

Deliver customs compliance advisory, including HS classification, valuation, origin rules, audit support, and risk mitigation for cross-border trade.

Cybersecurity & Data Protection

Provide cyber security and data protection advisory, including governance, incident response readiness, remediation, and compliance for cross-border data transfers.

Dispute Resolution

Handle commercial dispute resolution through negotiation, mediation, arbitration, and litigation, with strategy design and end-to-end case management.

Due Diligence

Conduct legal, financial, tax, and compliance due diligence to identify key risks, validate assumptions, and support decision-making and deal structuring.

Environmental Compliance

Advise on environmental compliance, permitting, EHS management, and sustainability requirements, helping clients assess and remediate environmental risks.

Export Controls & Compliance

Build export control compliance programs, classify controlled items, screen parties, manage licensing, and respond to enforcement inquiries across jurisdictions.

Host Country Investment Approvals

Obtain host-country investment approvals and sectoral permits, including foreign investment reviews, licensing, and registrations to enable smooth project implementation.

Human Resources

Provide HR advisory across hiring, compensation, policies, and labor compliance, including cross-border assignments and workforce optimization.

Initial Public Offering (IPO) & Listing

Guide IPO readiness and listing execution, including governance enhancement, regulatory compliance, prospectus support, and coordination with intermediaries.

Insolvency & Restructuring

Advise on insolvency proceedings and restructuring plans, including creditor negotiations, debt reorganization, and asset dispositions to preserve value and continuity.

International Engineering Contracting (EPC)

Advise on international engineering contracting (EPC), covering bid strategy, contract drafting/negotiation, claims management, compliance, and dispute prevention.

International Logistics

Provide international logistics planning and coordination, optimizing routes, costs, and timelines while aligning with trade terms, customs requirements, and risk controls.

Investment Agreement Drafting & Review

Draft, review, and negotiate investment agreements (term sheets, SPA/SSA, shareholders' agreements), aligning risk allocation, control rights, and closing conditions.

Investment Target Screening & Matching

Screen, benchmark, and match investment targets to client strategy through industry mapping, financial filters, and fit assessments to build a qualified pipeline.

Legal Entity Establishment & Maintenance

End-to-end incorporation and lifecycle maintenance, including registrations, corporate secretarial filings, governance updates, and ongoing compliance in relevant jurisdictions.

Life Sciences

Offer life sciences regulatory and transaction support, covering market access, clinical/quality compliance, licensing, and industry-specific risk management.

Ongoing Legal Counsel

Serve as ongoing legal counsel, providing day-to-day advisory, contract review, compliance support, and rapid response for operational legal issues.

Other Trade-related Services

Offer trade-related support such as trade finance, trade insurance, customs clearance/inspection, agency services, export tax rebates, and product certification & testing.

Securities / Funds / Futures / Insurance / Credit

Advise on financial services matters across securities, funds, futures, insurance, and credit, including licensing, compliance, product structuring, and reporting.

Tax Planning

Design tax-efficient structures, manage transfer pricing considerations, mitigate double taxation, and support filings to optimize tax costs while maintaining compliance.

Technology & Intellectual Property

Support technology and IP strategy, including IP portfolio planning, filings, licensing, technology transfer, and protection of core innovations.

Global Reach

China’s changing regulatory environment and increasingly competitive landscape require medical device companies to develop a localized strategy to enter the Chinese market. As China's leading medical device CRO (including IVD), our expertise and enriched project experiences can help our clients to navigate cultural differences, monitor regulatory changes, and marketize our clients’ products in the most efficient and cost-effective way. Since 2000, we have collaborated with top 20 global medical device companies and worked with more than 600 clients overseas to successfully launch their products in China. Globally, Tigermed-Jyton have established long-term cooperation with more than 1900 medical device R&D and manufacturing enterprises from more than 30 countries, and have set up more than 180 global offices worldwide. With our SOPs and QMS complying with global standards, we offer regulatory affairs and clinical trial services in all major markets. We have global teams of specialists and professionals expertizing in local regulations. With a solid team based in China, Tigermed-Jyton has cost advantages, offering top-tier services such as global study clinical operation, data management & biostatistics, medical affairs, and more.

Beijing Tigermed-Jyton Co., LTD.

IVD——Product Manufacturing and Quality System

We provide the following product production and quality system related services: 1. MAH policy consultation 2. ISO 13485 and ISO 9001 certification guidance 3. Full lifecycle quality system service 4. GMP workshop design counseling and on-site review 5. Product production and quality control under the GMP environment 6. Third-party audit of quality systems 7. Computer information management system 8. Risk management guidance: Registration application and post-marketing follow up study

Beijing Tigermed-Jyton Co., LTD.

IVD——Clinical Trial Services

We are experienced in providing clinical trial services for IVDs. In accordance with current regulations, GCP and corresponding guidelines, we can provide clinical trial related services for: 1. Registrational clinical trial 2. Real-world study 3. Analysis performance studies 4. Reference range studies 5. Exploratory clinical studies 6. Product R&D stage and post-market clinical studies 7. Registrational clinical evaluation Related services cover: 1. Product clinical study design 2. Third-party audits 3. Clinical trial project management and tracking 4. Data management and EDC software system 5. Clinical trial statistics support 6. Clinical trial report writing

Beijing Tigermed-Jyton Co., LTD.

IVD——China and Global Registration Services

Reflected in policies and regulations, different countries have different risk classifications and review requirements for IVDs. The reform of the review and approval system for IVDs is deepening constantly in China. With the industry development, global promotion of products speeds up, and the need of global distribution of products increases continuously. As a global CRO, Tigermed-Jyton can provide regulatory support for China NMPA and global registration for the IVD products. Services related to product registration, covering various risk levels, including initial registration, changes, and certificate extensions: 1. Preparation of product technical requirements 2. Product registration testing / third-party testing 3. Preparation of product registration dossiers and pre-evaluation / third-party pre-evaluation 4. Evaluation process tracking, coordination and communication 5. Preparation and feedback of supplementary information

Beijing Tigermed-Jyton Co., LTD.

IVD——Agent Related Services

We can serve as customer’s legal representative to handle product registration / filing, post-marketing regulatory activities, and communication with relevant authorities. We have a history of over a decade in providing agent services and has developed a comprehensive and mature process with extensive experience in this field. We offer the following services: 1. Assist in communication with the corresponding regulatory authorities 2. Convey regulations and standards to manufacturing company 3. Collect post-marketing AEs and report them to authorities / manufacturers 4. Assist in handling recalls and report to authorities 5. Assist manufacturers in handling other post-market regulatory tasks

Beijing Tigermed-Jyton Co., LTD.

IVD——Product Classification Service

Each country implements classified and graded management for products with different risks. The regulation and control over the full life cycle of the products, including R&D, manufacturing, operation, registration and clinical use, are different for products in different categories. To avoid over or insufficient management caused by ambiguous product classification, and to provide references for reasonable and efficient resource allocation for the enterprise and regulatory authorities, we provide the following product classification service for enterprises. 1. Classification documents preparation guidance 2. Track the application process

Beijing Tigermed-Jyton Co., LTD.

IVD——Regulatory Consultation Service

At present, relevant policies and regulations on medical devices change frequently globally and requirements are becoming increasingly stringent, leading the increasing compliance cost. We provide full lifecycle regulatory services on IVD products for the client and promote product compliance. 1. China and global regulatory consultation 2. China and global regulatory training and interpretation 3. Strategy design and assessment 4. Regulatory update

Beijing Tigermed-Jyton Co., LTD.

IVD——Product Design and Development

Our IVD team has rich experience in serving the innovative development of IVD products. We can provide customers with regulatory and systematic services during the product design and development stages. 1. Establishment of the R&D quality system 2. Product registration strategy (Product development consultation report) 3. Input and output support during the R&D stage 4. Product verification and design validation 5. Technical documentation guidance 6. Design translation guidance 7. Analysis Performance studies 8. Reference range studies 9. Exploratory clinical studies

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Global Medical Device Registration

We have offices around the world, and have maintained close contact with the local authorities. Through analyzing the specific cases of medical devices companies and manufacturers, we provide more direct and professional guidance, along with reasonable marketing strategies. We offer professional medical device registration services globally and is currently committed to the registration approval certification of CE (MDR, IVDR, PPE, AIMDD), FDA (listed, 510K, PMA), Japan, South Korea and other countries.

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——China NMPA Registration Services

Medical devices, which are / will be marketed and used in the People’s Republic of China, shall be registered / filed with the NMPA / local authorities. We can recommend the product registration path for companies, formulate the most reasonable marketing strategy, give warning to possible risk points in advance, and provide reasonable suggestions for risk avoidance to improve the efficiency and to increase success rate of product approval. We can provide you with the proper services regardless of the status of the product. Our services include but not limited to: 1. Product Classification Application / Attribute Application 2. Class I device filing / change filing 3. Class II / III device initial registration 4. Class II / III device renewal registration 5. Change filing of Class II / III device 6. Change registration of Class II / III device 7. Clinical trial application 8. Intent for Use (IFU) changes 9. Medical device certificate re-issuance / error correction / cancellation 10. Other green channel applications, such as innovation application, priority review, emergency use approval, etc

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Agent Related Services

We can serve as customer’s legal representative to handle product registration / filing, post-marketing regulatory activities, and communication with relevant authorities. We have a history of over a decade in providing agent services and has developed a comprehensive and mature process with extensive experience in this field. We offer the following services: 1. Assist in communication with the corresponding regulatory authorities 2. Convey regulations and standards to manufacturing company 3. Collect post-marketing AEs and report them to authorities / manufacturers; 4. Assist in handling recalls and report to authorities 5. Assist manufacturers in handling other post-market regulatory tasks 6. Preparation of annual risk assessment reports 7. Assist in handling random market inspections 8. Assist in handling medical insurance consumables system management and post-market regulatory support 9. Advertising approval 10. Assistance in processing UDI code registration

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Regulatory Consultation

If medical device manufacturers / agents / distributors have any pre-market system, registration, clinical, and post-market regulatory queries, we can provide professional regulatory consultation service. We will comprehensively consider the possible risks involved in all aspects of the queries raised, integrate the relevant resources of the company, help customers consider the overall situation, and avoid subsequent hidden problems. 1. System / Registration / Clinical Query Clarification 2. Strategy planning 3. Regulation and policy interpretation 4. Testing consultation 5. Registration documentation review

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Third-party Audit

We have a complete quality management system for clinical trials of medical devices. Our audit team has an average industry experience of over 10 years. Our audit team members not only possess practical experience in the industry but also come from diverse backgrounds, including hospital institutions and national agencies. This allows us to conduct thorough evaluations of projects from a professional standpoint. The audit team is familiar with ICH-GCP and local authorities’ relevant regulations of medical device clinical study, experienced in quality management, able to comprehensively audit the clinical trial, and is actively providing high-quality audit service for clients. Our range of services includes: 1. On-site audits for medical device clinical trials and in vitro diagnostic product clinical trials study sites, as well as office audits for study documents (TMF). 2. System audits and third-party supplier audits of such as SMO (Site Management Organization) and central laboratories. 3. Preparations and support for sponsor and NMPA inspections. 4. Establishment of GCP full life cycle quality management system (QMS) for sponsors. 5. Registration of medical device clinical trial institutions.

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Computerized Digital Systems

We continuously and actively explore digital and innovative business models and make forward-looking arrangements. We can provide the following digital systems to our customers: 1. EDC – Electronic Data Capture System 2. IWRS – Interactive Web Response System 3. CTRM – Clinical Trial Remote Monitoring System 4. ePRO – Electronic Patient Reported Outcome System 5. eSafety – Pharmacovigilance system 6. CTMS – Clinical Trial Management System 7. eTMF – Electronic Trial Master File System

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Data Management and Statistical Analysis

Our DMSA team is data sensitive, has a strong study design background, and is good at DMSA of drugs and devices. We have a number of international statistical professionals. The team maintains a low turnover rate and high growth trend. Our senior statisticians have work experience of nearly 10 years in this field on average. We are expert in providing medical and statistical support for device submissions in the United States, Europe, China and other countries and regions, and have extensive experience with hundreds of projects. Our Aata team holds the following data management authorization certificates: 1. The only CRO company authorized by MediData Rave® in China 2. The first company in Asia which signed the CRO advantage projects with Oracle 3. Hold 10 Oracle certificates 4. Other certificates such as WHO-DD and MedDRA Our main data management systems include: 1. Oracle Clinical & Oracle Remote Data Capture 2. MediData Rave 3. InForm 4. ClinstReport 5. Clinflash Our main data management services include: 1. Data management consulting and training 2. Paper and EDC project 3. Case report form design 4. Build and validate database 5. Develop data management plan 6. Develop data validation plan 7. Edit check programming and testing 8. Double data entry and check 9. Electronization of data and manual review 10. Resolution of data queries 11. Medical coding 12. SAE reconciliation 13. Processing of external data 14. Database quality control 15. Blinded data review 16. Database lock 17. Data extraction and transfer 18. Preparation of data management report The range of biometric services we provide: 1. Offer comments to the Chinese Biostatistics Society as an expert, and participate in data standard setting, quality and biostatistics related projects of NMPA 2. Clinical trial design and consulting 3. Provide statistical support for the study protocol 4. Calculate the sample size / power 5. Randomizing design and coding 6. Develop statistical analysis plan 7. Prepare templates of statistical tables, figures and listings 8. Statistical programming 9. Generate data analysis set 10. Generate tables, figures and listings (TFLs) 11. Interim analysis and statistical support for the Data Monitoring Committee 12. Comprehensive summary and analysis of safety and efficacy 13. Statistical analysis report 14. Statistical support for the clinical study report 15. Statistical support for registration application 16. Statistical support for journals of various therapeutic fields, conference materials, posters and manuscripts

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Medical Monitoring

Our professional medical monitors can help the project team to better understand the objective, inclusion & exclusion criteria and process of the clinical trial, to provide medical support for the project team, and to ensure the safety of the subjects and the accuracy of the clinical trial data. The medical monitoring team will provide the following services for the client: 1. Draft / update the medical monitoring plan 2. Medical training (medical monitoring plan / protocol interpretation / knowledge of relevant disease areas) 3. Subject eligibility review 4. Regular medical monitoring meeting 5. Protocol violation / deviation review 6. Medical review for clinical data (adverse events, laboratory data, vital signs, medical history, and concomitant medication, etc.) 7. Medical consulting / Q&A Log maintenance 8. Review of clinical trial-related materials (clinical trial protocol, clinical summary report, and case report form, etc.) 9. Review of laboratory alert values 10. Data cleaning before database lock

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Safety Vigilance

With stable and high-quality team members, our safety vigilance and medical monitoring team can provide professional services needed by the client. We also have an intact and mature SOP system and rich experience in international project management. We offer the following services: 1. Review the study protocol; 2. Develop safety management plan 3. Review CRF and conduct relevant medical training 4. Collection, collation and classification of SAEs 5. SAE reconciliation 6. Preparation of SAE reports and submission to relevant regulatory authorities and sponsors 7. Support safety review committees (SRC) and independent data monitoring committees (IDMC) 8. Periodic safety reports 9. Clinical trial summary report review 10. Post-market risk analysis report and re-evaluation report

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Project Management

We have a senior project management team with years of expertise in various fields such as medical aesthetics, cardiovascular, ophthalmology, AI, surgical robots, and oncology. We have built thorough analysis of the current situation and future developments in these fields. Relying on a strong medical team and years of solid cooperation with the study sites, we have accumulated unique advantages and rich experiences in the project management for innovative devices. Tigermed-Jyton is customer-oriented and adopts a project management model where the project manager serves as a one-stop contact point for the sponsors, assisting them in coordinating other functional teams to improve communication efficiencies. The project manager regularly analyzes the deviations between plans and actual progress, as well as manages and prevents risks, ensuring that the project proceeds as scheduled. 1. Preparation of project plan 2. Clinical trial risk management 3. Clinical trial document management 4. Clinical trial financial management 5. Clinical trial meeting organization 6. Project training 7. Relevant supplier management

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Clinical Monitoring

We have a monitoring team with more than 200 CRAs in China, and more than 800 CRAs globally. We can provide local clinical monitoring and site management services. We are familiar with the study site process, and provide more convenient support and more professional services for the study sites. Our services include: 1. Study site screening 2. Ethics Committee filing and approval 3. Study site clinical trial agreement negotiation 4. Study site initiation and close-out 5. Study site monitoring and management 6. Investigational product management

Beijing Tigermed-Jyton Co., LTD.

Beijing Tigermed-Jyton Co., LTD. ——Medical Writing

The medical writing team consists of dozens of excellent medical experts, writing specialists and statisticians. Core members have an average industry experience of more than 10 years and academic background of leading medical schools globally. Our innovative protocol design concept, scientific and rigorous work style, rich medical writing experience and effective SOPs have won the team a good reputation in the industry. Our service content includes the following: 1. Design of clinical trial protocols for medical devices / different phases of clinical trial protocols or unconventional study protocols for drugs 2. Preparation of clinical protocol related documents (e.g., case report forms, informed consent forms, and investigator’s brochure) 3. Preparation of clinical study report 4. Publishing papers on core journals 5. Preparation of medical materials for clinicians (e.g., questionnaire on updating treatment guidelines)

Beijing Tigermed-Jyton Co., LTD.

A Director's Perspective: Exposure, Risks and Personal Liability

In this article, Mark Lee Chambers Law Corporation explores the fundamental paradox facing corporate leaders: while the company itself operates under the shield of limited liability, directors remain exposed to direct personal liability when breaching their duties.

Mark Lee Chambers Law Corporation

Shareholders' Agreement

This Article by Mark Lee Chambers Law Corporation explains the importance behind a well drafted and comprehensive agreement between shareholders and examines both the legal underpinnings of these contracts and explores practical options for allocating rights and liabilities across different business scenarios.

Mark Lee Chambers Law Corporation

Shareholder Disputes: Oppression, Buyout Orders, Share Valuation

This Article by Mark Lee Chambers Law Corporation explores both the legal and technical aspects of shareholder oppression claims and business / share valuations.

Mark Lee Chambers Law Corporation

Shareholder Decisions - The Power of the Vote

When corporate management is vested solely in the Board, can shareholders ever make business decisions for the company? This Article by Mark Lee Chambers Law Corporation examines the rare exceptions to this rule and outlines the factors courts consider when allowing shareholders to intervene in corporate management.

Mark Lee Chambers Law Corporation

Shareholder - The Concept of Rights & Liabilities

This Article by Mark Lee Chambers Law Corporation examines the legal relationship between a company and its shareholders post-incorporation, focusing on the specific rights shareholders retain when day-to-day management is vested entirely in the Board.

Mark Lee Chambers Law Corporation

Share Buyout - Applicability of Discounts

When courts find shareholder oppression, a share buyout is a common enough remedy to the aggrieved shareholder. This Article by Mark Lee Chambers Law Corporation discusses the circumstances under which valuation discounts may be applied when the court orders a buyout to remedy the oppression.

Mark Lee Chambers Law Corporation

Power to Grant Relief - A Director's Liability under Section 391 of the Companies Act 1967

This Article by Mark Lee Chambers Law Corporation explores the reliefs a director might seek under section 391 of the Companies Act 1967 when facing legal action for a breach of director's duties.

Mark Lee Chambers Law Corporation

Testifying from Outside Singapore - the Video Link Exception in Multi-Jurisdictional Disputes

With multi-jurisdictional disputes on the rise and the unavoidable need for witness testimony, this Article by Mark Lee Chambers Law Corporation explores the general principles and considerations factored by the Singapore Courts in deciding whether to exercise its discretion to receive oral evidence by video link in civil proceedings.

Mark Lee Chambers Law Corporation

Lifting the Veil of of Incorporation

This Article by Mark Lee Chambers Law Corporation discusses the concept of the separate legal personality following the incorporation of a company in Singapore.

Mark Lee Chambers Law Corporation

Investing in Singapore: A Foreign Investor's Guide

This Joint Article between Marigold Consultancy and Mark Lee Chambers Law Corporation presents a bite-sized roadmap for readers looking to expand or anchor their businesses in Singapore.

Mark Lee Chambers Law Corporation

Directors - The Concept of Duties & Liabilities

This Article by Mark Lee Chambers Law Corporation discusses the concept of directorships in Singapore and explains that while the law recognises only one form of directorship, in practice, there are several kinds of directors including executive and non-executive directors. All owe fiduciary duties to the company.

Mark Lee Chambers Law Corporation

Derivative Action by Shareholders

This Article by Mark Lee Chambers Law Corporation discusses the very common scenario of a deadlock between a company and its shareholders. We discuss specific circumstances where a shareholder's request for enforcement and accountability are rebuffed by the Board.

Mark Lee Chambers Law Corporation

Companies - Corporate Personality

This Article by Mark Lee Chambers Law Corporation provides an overview on how companies are incorporated in the Republic of Singapore and explains the effects of incorporation and the relationships between the company and its shareholders after incorporation.

Mark Lee Chambers Law Corporation

Case Update: Sakae Holdings Ltd [2018] SGCA 33

This Case Update by Mark Lee Chambers Law Corporation discusses the decision made by the highest court in the Republic of Singapore relating to minority oppression claims brought under Section 216 of the Companies Act 1967. The important distinction is drawn between personal wrongs suffered by a shareholder and corporate wrongs committed against the company, and in what situations may a finding of commercial unfairness be found to support a claim for oppression.

Mark Lee Chambers Law Corporation

Case Highlight: Reverse Oppression

This Case Highlight by Mark Lee Chambers Law Corporation discusses the topic of whether a majority shareholder may ever be "oppressed" by the minority.

Mark Lee Chambers Law Corporation

Case Highlight: Shareholder Oppression and the Relevance of a Buyout Remedy

This Case Highlight by Mark Lee Chambers Law Corporation discusses a decision made by the High Court of the Republic of Singapore to dismiss an application made by the majority shareholders to strike out a minority shareholder's claim for oppression, on grounds that a buyout offer had already been made. The majority shareholders' application was successfully resisted.

Mark Lee Chambers Law Corporation

Access to a Company's Documents & Records

This Article by Mark Lee Chambers Law Corporation explores a director's rights of inspection vis-a-vis company documents and the avenue one has when his/her entitlement is restricted.

Mark Lee Chambers Law Corporation

Legal Update – February 2026 – The Law on Investment 2025, Effective from 1 March 2026, Introduces Key Changes for Investors and Enterprises

The period from 2020 to 2025 has been marked by significant geopolitical volatility. Investment activities and global supply chains have undergone substantial restructuring. It is widely observed that investment flows in general, and next-generation foreign direct investment (FDI) in particular, are no longer primarily driven by low-cost advantages or short-term incentives. Instead, they are increasingly oriented toward jurisdictions offering stable investment environments, well-integrated political, social, environmental, and technological infrastructure, and a strong commitment to sustainable development standards.

Bizconsult Law Firm

Special Report on Nutrition and Health Foods for China’s Middle-Aged and Elderly Population

As China’s population aging continues to deepen, nutritional and health issues among the middle-aged and elderly have become increasingly prominent, making this an important component of advancing the Healthy China strategy. Demand from middle-aged and elderly consumers in the nutrition products sector continues to grow, driving steady expansion of the nutrition and health food market, while consumer needs are becoming increasingly diversified and precise. Against this backdrop, based on in-depth research into the field of nutrition and health for China’s middle-aged and elderly population, CIC and QuantumPharm/Quantum Song? Wait—need accurate translation. Better neutralize: CIC Insight Consulting and Quantum Song (NASDAQ: QSG) jointly released the 2024 China Middle-Aged and Elderly Nutrition and Health Food Report: Nourishing the Silver Years, Insights into the Consumption Landscape of Nutrition and Health Among Middle-Aged and Elderly Consumers. The report provides a comprehensive analysis of the current state of nutrition and health consumption among China’s middle-aged and elderly population, key trends and characteristics, consumer pain points, and future industry development trends.

China Insights Consultancy

White Paper on the New-Style Tea Beverage Industry

Recently, the 2nd China New-Style Tea Beverage Industry Conference, hosted by the China New-Style Tea Beverage Industry Alliance, was successfully held at the National Exhibition and Convention Center in Shanghai. During the conference, CIC, together with the China New-Style Tea Beverage Industry Alliance, jointly released the White Paper on the New-Style Tea Beverage Industry. Zhu Yue, Partner at CIC, attended as a representative of the invited consulting institution and joined more than 100 tea beverage brands from across the country to explore breakthrough paths under the theme of “Differentiation • A New Journey.” Zhu Yue stated that the new-style tea beverage industry is undergoing continuous innovation and transformation, and that the White Paper on the New-Style Tea Beverage Industry addresses issues of market concern from multiple perspectives, including recent investment hotspots, interpretation of the industry chain, and industry development trends, giving it important practical and strategic significance in the current environment. The white paper received strong attention and praise from conference guests and continued to generate significant interest after the event.

China Insights Consultancy